5 Key Takeaways

• 1

  Switching to Dovato (DTG/3TC) resulted in a lower proportion of steatotic liver disease compared to Biktarvy (BIC/FTC/TAF) in HIV-1 suppressed adults.

• 2

  The PASO DOBLE study is the largest phase IV trial comparing DTG/3TC and BIC/FTC/TAF in adults with suppressed HIV-1.

• 3

  At Week 96, SLD was reported in 49% of BIC/FTC/TAF recipients versus 29% of DTG/3TC recipients, indicating a significant difference.

• 4

  Among participants with ≥5% weight gain, SLD occurred in 76% on BIC/FTC/TAF compared to 17% on DTG/3TC, highlighting treatment differences.

• 5

  Dovato is approved for HIV-1 treatment in adults and certain adolescents without known resistance to integrase inhibitors or lamivudine.